Corient Private Wealth LLC Sells 1,615 Shares of Waters Co. (NYSE:WAT)

Corient Private Wealth LLC decreased its stake in shares of Waters Co. (NYSE:WAT - Free Report) by 22.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 5,564 shares of the medical instruments supplier's stock after selling 1,615 shares during the period. Corient Private Wealth LLC's holdings in Waters were worth $2,064,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. Bank of Jackson Hole Trust purchased a new position in Waters during the fourth quarter worth about $34,000. Fortitude Family Office LLC grew its holdings in shares of Waters by 235.7% during the fourth quarter. Fortitude Family Office LLC now owns 94 shares of the medical instruments supplier's stock worth $35,000 after purchasing an additional 66 shares in the last quarter. Steward Partners Investment Advisory LLC raised its stake in Waters by 129.3% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 94 shares of the medical instruments supplier's stock valued at $35,000 after purchasing an additional 53 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Waters by 54.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 125 shares of the medical instruments supplier's stock valued at $46,000 after purchasing an additional 44 shares during the last quarter. Finally, R Squared Ltd bought a new stake in Waters during the fourth quarter valued at approximately $63,000. Institutional investors own 94.01% of the company's stock.

Analyst Upgrades and Downgrades

WAT has been the subject of a number of recent research reports. Wells Fargo & Company boosted their target price on Waters from $415.00 to $420.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. StockNews.com lowered shares of Waters from a "buy" rating to a "hold" rating in a research report on Tuesday, February 25th. Barclays upgraded Waters from an "underweight" rating to an "equal weight" rating and raised their price target for the stock from $360.00 to $415.00 in a research report on Monday, February 10th. Sanford C. Bernstein upgraded shares of Waters from a "market perform" rating to an "outperform" rating and set a $430.00 price objective on the stock in a research report on Friday, January 10th. Finally, JPMorgan Chase & Co. lifted their price objective on Waters from $380.00 to $390.00 and gave the company a "neutral" rating in a research report on Thursday, March 6th. Eleven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Waters has a consensus rating of "Hold" and an average target price of $391.07.

Remove Ads

Waters Stock Performance

Waters stock traded down $5.09 during midday trading on Tuesday, hitting $368.21. The stock had a trading volume of 456,859 shares, compared to its average volume of 440,020. Waters Co. has a 52-week low of $279.24 and a 52-week high of $423.56. The company has a market capitalization of $21.88 billion, a PE ratio of 34.38, a P/E/G ratio of 3.79 and a beta of 1.00. The firm's fifty day moving average is $390.29 and its two-hundred day moving average is $371.85. The company has a current ratio of 0.94, a quick ratio of 0.65 and a debt-to-equity ratio of 1.14.

Waters (NYSE:WAT - Get Free Report) last issued its earnings results on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share for the quarter, topping the consensus estimate of $4.02 by $0.08. Waters had a net margin of 21.56% and a return on equity of 46.31%. On average, research analysts forecast that Waters Co. will post 12.86 EPS for the current year.

Waters Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.